Serum concentrations of Helicobacter pylori IgG and the virulence factor CagA in patients with ischaemic heart disease
AbstractTo compare the serum concentrations of IgG to Helicobacter pylori and its virulence factor CagA in patients with ischaemic heart disease [IHD], we recruited 120 patients with IHD [acute myocardial infarction [AMI] [n = 60]; unstable angina [UA] [n = 60]] and 60 sex- and age-matched healthy controls in this study. The seroprevalence of anti-H. pylori IgG was 86.7% in AMI, 91.7% in UA patients and 58.3% in the control group with mean titres of 33.2 U/ml [standard error [SE] 4.76], 57.96 U/ml [SE 7.54] and 25.72 U/ml [SE 4.01] respectively. The seroprevalence of anti-H. pylori in the patient groups was significantly higher than the control group. The mean levels of anti-H. pylori in the AMI and UA groups were also significantly higher than in the control group. The seroprevalence and mean titre of anti-CagA IgG did not differ significantly between patient and control groups
Jafarzadeh, A., Esmaeeli Nadimi, A., Nemati, M., Tahmasbi, M. & Ahmadi, P. (2010). Serum concentrations of Helicobacter pylori IgG and the virulence factor CagA in patients with ischaemic heart disease. EMHJ - Eastern Mediterranean Health Journal, 16 (10), 1039-1044, 2010 http://www.who.int/iris/handle/10665/118000
JournalEMHJ - Eastern Mediterranean Health Journal, 16 (10), 1039-1044, 2010
MetadataShow full item record
Showing items related by title and MeSH subject.
Zahran, S.M.; Hamed, N.A.; Dafrawy, M.; Abdelaziz, H.K.; Morsi, M.G. (2013)To test the role of T helper cell Th1 immunity we recruited 24 patients with idiopathic thrombocytopenia associated with H. pylori seropositivity. They were divided into 2 groups: 12 with immune-mediated thrombocytopenia [Group 1] and 12 with non-immune mediated thrombocytopenia [Group 2]. We also recruited 10 individuals seronegative for H. pylori [Group 3] as controls. Initial platelet count was significantly lower in Group 1 than Group 2. H. pyloriwas eradicated in 10 of 12 patients in Group 1 and in all patients in Group 2. Transient improvement ...